The makers of Ozempic and Zepbound are fighting to stop compounded copies of their drugs. But it’s unclear whether they can ...
The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.
Novo Nordisk and Eli Lilly are facing scores of personal injury claims for allegedly failing to warn patients about side ...
Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...
Below, I'll break down what's going on at Viking and explain how the company may emerge as a competitive force in the weight ...
A Goldman Sachs economist has suggested that the US economy could experience accelerated growth with increased use of GLP-1 ...
Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...
In the United Kingdom, the government is hoping weight loss drugs might improve public finances, eyeing their use to help ...
Eli Lilly proposed a plan to ensure 340B entities pay no more than the ceiling price by providing them with cash directly on ...
Diane Brady: Leadership Next is powered by the folks at Deloitte who, like me, are exploring the changing roles of business ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback